Efficacy and Safety of Intranasal Glucagon for Treatment of Induced Hypoglycemia in Adults with Diabetes

Principal Investigator

Andrew Ahmann

Study Purpose

The purpose of this study is to test the safety and effectiveness of emergency glucagon given as a spray into the nose, when compared with glucagon given by injection.

Medical Condition(s)

Type 1 and Type 2 diabetes mellitus

Eligibility Criteria

18-64 years old
Diagnosed with type 1 diabetes for at least 2 years and using insulin therapy since diagnosis
Diagnosed with type 2 diabetes and using multiple daily insulin therapy for at least 2 years
BMI that is not too low or too high
Must not be pregnant
Have not experienced a very low blood sugar that required assistance from another person for treatment in the last month
Do not regularly drink 3 or more alcoholic beverages per day
Have not donated blood in the last 2 months
Have not participated in another study within the last month

Age Range

18 - 64

Healthy Volunteers Needed


Duration of Participation

3 visits to OHSU within 1-3 months. The first visit will last approximately 1.5 hours. Both the 2nd and 3rd visits will last approximately 6 hours.

Minors Included



Contact the OHSU Harold Schnitzer Diabetes Health Center Research Department at (503) 494-4704 or by email at DMResearchCenter@ohsu.edu for more information.


AMG Medical, funded by the Leona M. and Harry B. Helmsley Charitable Trust

Recruitment End


Compensation Provided



All study-related care is provided at no cost to qualified participants including physical examinations. Compensation of up to $500 will be provided.

Go Back